Cherkasov V L, Bol'shakova T D, Kuznetsov V A, Obrazberdyev S, Mikerin S M
Vrach Delo. 1990 Apr(4):113-5.
Amben (fibrinolysis inhibitor) and parmidin (bradykinin inhibitor) were used as pathogenetic treatment of 38 and 36 patients with hemorrhagic erysipelas respectively. Early amben treatment proved clinically rather effective and was accompanied by normalization of fibrinolysis and kallikrein-kinin system. Parmidin treatment resulted only in pain control, other subjective signs, normalization of the kallikrein-kinin system while fibrinolysis activity was maintained at former levels.
氨苯(纤维蛋白溶解抑制剂)和巴马亭(缓激肽抑制剂)分别用于38例和36例出血性丹毒患者的病因治疗。早期氨苯治疗在临床上证明相当有效,同时纤维蛋白溶解和激肽释放酶 - 激肽系统恢复正常。巴马亭治疗仅能控制疼痛,其他主观症状有所改善,激肽释放酶 - 激肽系统恢复正常,但纤维蛋白溶解活性维持在先前水平。